European Commission: Pre-commercial Research and Innovation Procurement

Deadline: 21-Apr-22

European Commission is calling for proposals for Pre-commercial research and innovation procurement (PCP) for building the resilience of health care systems in the context of recovery.

Scope

Pre-commercial procurement (PCP) can boost innovation in health care systems, while building the capacity of providers and increasing resilience and preparedness in the context of cross-border public health emergencies. Through the competitive development of a range of breakthrough innovations for a concrete health care challenge, PCP can strengthen the security of the supply chain in the health care sector. At the same time, these instruments can support the economic recovery of the EU by providing incentives to the EU health and technology industry (especially spin-offs, start-ups and SMEs) to innovate and commercialise their products or services at a larger scale than they normally would. Fostering the development of such innovative solutions in Europe can reinforce EU strategic autonomy in strategic health technologies and lead to the creation of new markets for the EU industry, thereby contributing to EU growth, employment and competitiveness. At the same time, joint/collaborative demand-side initiatives can help create economies of scale and early adoption of innovations by the health sector. Advances in this area can help EU health care systems build resilience and respond to public health threats better than if they would act individually.

Funding Information

The check will normally be done for the coordinator if the requested grant amount is equal to or greater than EUR 500 000, except for:

• public bodies (entities established as a public body under national law, including local, regional or national authorities) or international organisations; and
• cases where the individual requested grant amount is not more than EUR 60 000 (lowvalue grant).

Expected Outcomes

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 4 “Ensuring access to innovative, sustainable and high-quality health care”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to some of the following expected outcomes:

• Public and private procurers in the area of health care procure the competitive development of market-ready, sustainable, innovative solutions (materials, equipment, technologies and systems/practices) which are made in Europe and can improve the preparedness and resilience of health care systems in the context of the recovery;
• European health and technology industry actors (including start-ups/SMEs) bring to the market secure, interoperable digital health care solutions (complying with relevant ethical and privacy protection standards) which are proven to improve health outcomes and access to care for patients;
• Procurers facilitate the commercialisation of innovative solutions at a large scale (EU/international) by their successful suppliers through providing them with first customer references for the validation and first pilot deployment in multiple countries and health care settings;
• Policymakers, health care providers and professionals, patients and their carers – each in their respective areas – exchange and adopt good practices and the best solutions the market can deliver to improve the resilience of health care systems.

Eligibility Criteria

To be eligible for funding, applicants must be established in one of the eligible countries, i.e.:

• the Member States of the European Union, including their outermost regions;
• the Overseas Countries and Territories (OCTs) linked to the Member States;
• eligible non-EU countries:
  • countries associated to Horizon Europe
  • low- and middle-income countries

For more information, visit European Commission.

For more information, visit https://bit.ly/3DoHNmO